Financhill
Back

Sarepta Therapeutics Quote, Financials, Valuation and Earnings

Sarepta Therapeutics Price Quote

$109.05
-3.43 (-3.05%)
(Updated: November 14, 2024 at 5:55 PM ET)

Sarepta Therapeutics Key Stats

Sell
31
Sarepta Therapeutics (SRPT) is a Sell

Day range:
$111.53 - $116.30
52-week range:
$78.67 - $173.25
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.01
P/B ratio:
8.94%

Volume:
957.7K
Avg. volume:
935.6K
1-year change:
41.18%
Market cap:
$10.9B
Revenue:
$1.2B
EPS:
$1.54

How Much Does Sarepta Therapeutics Make?

Is Sarepta Therapeutics Growing As A Company?

  • What Is Sarepta Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.41%
  • What Is Sarepta Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sarepta Therapeutics Stock Price Performance

What Is Sarepta Therapeutics 52-Week High & Low?

Sarepta Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sarepta Therapeutics?

Is Sarepta Therapeutics Cash Flow Positive?

  • What Is SRPT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$352.5M
  • What Is Sarepta Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $77.8M
  • What Is Sarepta Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$72.9M

Sarepta Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SRPT return on invested capital is 5.51%
  • What Is Sarepta Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 3.67%
  • What Is SRPT Return On Equity?
    ROE is a measure of profitability and is 12.48%

Sarepta Therapeutics Earnings Date & Stock Price

Sarepta Therapeutics Competitors

  • Who Are Sarepta Therapeutics's Competitors?
    Below is a list of companies who compete with Sarepta Therapeutics or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Biomarin Pharmaceutical Inc (BMRN)
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Cytokinetics Inc (CYTK)
    • Vertex Pharmaceuticals Inc (VRTX)

Sarepta Therapeutics Dividend Yield

Sarepta Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 66.97%
Revenue: 40.79% 15.33%

Analyst Recommendations

Buy Recommendations: 12
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 189.86
Upside from Last Price: 68.8%

Major Shareholders

  • How many SRPT shares are owned by institutional investors?
    148.1M SRPT shares are owned by institutional investors
  • How many SRPT shares are owned by insiders?
    15.5M SRPT shares are owned by insiders